This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

As obesity rates in the United States have reached 41.9 percent among adults, Xevant has released a new e-book, Navigating Obesity Care and GLP-1 Coverage: A Guide for Employers, designed to empower ...

A study found that disruptions in homeostasis from quick weight reduction by consuming GLP-1 drug can elevate cortisol - a ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

New drugs from public and private companies are ... These new challengers are anticipated to account for roughly $70 billion of the total GLP-1 market, which is expected to be worth $200 billion ...

From loss of skin elasticity to hair density, supplements that offer targeted support for GLP-1 users, as well as those that ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

The podcast features Numerator Chief Economist Leo Feler, who talks about the potential impact of GLP-1 drugs like Ozempic ...

Dr Daniel Rosen, who is a surgeon and obesity medicine specialist based out of New York, says a 'legitimate number' of his ...